TGFB1 and cancer: The ratio of luminescence signals during days 36–49 in PC3 and days 39–46 in PC9 with or without the preceding treatment with APT-β1-OMe-P was statistically unchanged, showing that TGF-β1 inhibition has no or little effect on re-treatment with anti-cancer drugs after withdrawal (Figures 4C, lower, and 4D, lower panel; Tables S3 and S4).